Skip to main content
letter
. 2023 Feb 17;18:11. doi: 10.1186/s13011-023-00519-0

Table 2.

Patient’s substance use treatment history and time to relapse

Year Treatment Time to relapse for both alcohol and tobacco use
2010 Admitted for inpatient rehabilitationa for 3 months 2 months after discharge
2013 Admitted for inpatient rehabilitationb for 3 months 1 month after discharge
2014 Admitted for inpatient rehabilitationa for 3 months 3 months after discharge
2017 Admitted for inpatient rehabilitationa for 3 months 4 months after discharge
April to July 2019

Admitted for inpatient rehabilitationb for 3 months; attended out-patient follow-up for 2 months

Received oral naltrexone 50 mg once daily for 5 months. After this, he had a naltrexone implant (765 mg) inserted because oral naltrexone was out of stock. He relapsed a week after the implant was inserted

Received nicotine replacement therapy and bupropion 150 mg once daily for tobacco use disorder for 3 months

2 months after discharge with naltrexone implant in-situ
February to August 2021

Admitted for inpatient rehabilitationb for 6 months

Received naltrexone 50 mg once daily for 6 months

Received nicotine replacement therapy for tobacco use disorder for 3 months. He did not receive bupropion because it was out of stock

2 weeks after in-patient treatment while on oral naltrexone

A decision was made to try IV ketamine in light of recent evidence showing efficacy for severe alcohol use disorder

atreatment was conducted in a residential setting that offers therapy based on alcohol anonymous and peer recovery support strategies

btreatment was conducted in a setting offering medically managed intensive in-patient services